3.39
price up icon7.28%   0.23
after-market 시간 외 거래: 3.39
loading

X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스

pulisher
Feb 23, 2026

ETF Watch: How much upside does X4 Pharmaceuticals Inc haveJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn

Feb 23, 2026
pulisher
Feb 22, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat

Feb 22, 2026
pulisher
Feb 21, 2026

Why X4 Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Final Week & Verified Chart Pattern Trade Signals - mfd.ru

Feb 21, 2026
pulisher
Feb 21, 2026

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Feb 21, 2026
pulisher
Feb 20, 2026

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and SchizophreniaA New Chemical Entity Opening New Horizons in Psychiatric Innovation - Morningstar

Feb 20, 2026
pulisher
Feb 20, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore

Feb 20, 2026
pulisher
Feb 20, 2026

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat

Feb 20, 2026
pulisher
Feb 19, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat

Feb 19, 2026
pulisher
Feb 19, 2026

AI Stocks: Will CADL stock go up in YEAR2025 Risk Factors & Precise Trade Entry Recommendations - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 18, 2026

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times

Feb 18, 2026
pulisher
Feb 18, 2026

Layoff Tracker: BMS, Catalent Further Whittle Workforces - BioSpace

Feb 18, 2026
pulisher
Feb 17, 2026

Can X4 Pharmaceuticals Inc. lead its sector in growthPortfolio Gains Summary & AI Based Trade Execution Alerts - mfd.ru

Feb 17, 2026
pulisher
Feb 16, 2026

X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan - MarketBeat

Feb 16, 2026
pulisher
Feb 16, 2026

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Feb 16, 2026
pulisher
Feb 15, 2026

Is X4 Pharmaceuticals Inc. forming a bullish divergenceWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - TMX Newsfile

Feb 14, 2026
pulisher
Feb 14, 2026

How X4 Pharmaceuticals Inc. stock trades before earningsQuarterly Market Review & Long-Term Capital Growth Strategies - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat

Feb 14, 2026
pulisher
Feb 12, 2026

115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Biopharma company Ligand to reveal 2025 results Feb. 26 - Stock Titan

Feb 12, 2026
pulisher
Feb 12, 2026

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 12, 2026
pulisher
Feb 11, 2026

Viking Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat

Feb 11, 2026
pulisher
Feb 10, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent

Feb 10, 2026
pulisher
Feb 09, 2026

New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - stocktitan.net

Feb 09, 2026
pulisher
Feb 09, 2026

Insider Returns Down To US$57k As X4 Pharmaceuticals' Stock Dips 11% - simplywall.st

Feb 09, 2026
pulisher
Feb 09, 2026

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat

Feb 09, 2026
pulisher
Feb 08, 2026

X4 Pharmaceuticals: Commercial Execution Takes Center Stage - AD HOC NEWS

Feb 08, 2026
pulisher
Feb 07, 2026

Aug Gainers: Can X4 Pharmaceuticals Inc sustain earnings growthWall Street Watch & Entry Point Confirmation Alerts - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 06, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2026
pulisher
Feb 06, 2026

Top Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool

Feb 06, 2026
pulisher
Feb 06, 2026

Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price - simplywall.st

Feb 06, 2026
pulisher
Feb 05, 2026

What is the fair value of X4 Pharmaceuticals Inc. stock nowMarket Sentiment Report & Community Consensus Picks - mfd.ru

Feb 05, 2026
pulisher
Feb 04, 2026

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire

Feb 04, 2026
pulisher
Feb 04, 2026

Pfizer Inc. - Britannica

Feb 04, 2026
pulisher
Feb 04, 2026

Prescription Drug Costs - Britannica

Feb 04, 2026
pulisher
Feb 03, 2026

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 - Yahoo Finance

Feb 03, 2026
pulisher
Feb 03, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $4.92 Consensus PT from Brokerages - Defense World

Feb 03, 2026
pulisher
Feb 03, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Average PT from Brokerages - Defense World

Feb 03, 2026
pulisher
Feb 02, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 02, 2026
pulisher
Feb 02, 2026

X4 Pharmaceuticals announces inducement grants under Nasdaq Listing Rule - marketscreener.com

Feb 02, 2026
pulisher
Feb 01, 2026

Moving Averages: How much upside does X4 Pharmaceuticals Inc have2025 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn

Feb 01, 2026
pulisher
Jan 31, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Jan 31, 2026
pulisher
Jan 29, 2026

More Than 30,000 Prescribed Cholesterol Drugs Recalled Nationwide - The Healthy @Reader's Digest

Jan 29, 2026
pulisher
Jan 28, 2026

Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st

Jan 28, 2026
pulisher
Jan 28, 2026

Exit Recap: Is X4 Pharmaceuticals Inc stock a value trapWeekly Stock Recap & AI Driven Stock Movement Reports - baoquankhu1.vn

Jan 28, 2026
pulisher
Jan 27, 2026

Budget pitch: Pharma Inc seeks tax breaks for research and development - The Economic Times

Jan 27, 2026
pulisher
Jan 27, 2026

CORRECTING and REPLACING -- BridgeBio Pharma Reports - GlobeNewswire

Jan 27, 2026
pulisher
Jan 25, 2026

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Jan 25, 2026
pulisher
Jan 25, 2026

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Jan 25, 2026
pulisher
Jan 24, 2026

Tarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Jennison Associates LLC - MarketBeat

Jan 24, 2026
pulisher
Jan 24, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat

Jan 24, 2026
pulisher
Jan 22, 2026

Telehealth deal lets U.S. travelers secure weekly malaria prevention pre-trip - Stock Titan

Jan 22, 2026
pulisher
Jan 22, 2026

31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Jan 22, 2026
pulisher
Jan 21, 2026

Aug Breakouts: What is the long term forecast for X4 Pharmaceuticals Inc stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 20, 2026

Lilly, Takeda targeted by legal strategy usually reserved for the mob - Pharma Voice

Jan 20, 2026
pulisher
Jan 20, 2026

Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan

Jan 20, 2026
$101.05
price up icon 0.20%
$28.26
price up icon 1.80%
$104.83
price up icon 1.10%
$110.89
price up icon 0.87%
$158.62
price down icon 0.26%
biotechnology ONC
$369.00
price down icon 0.44%
자본화:     |  볼륨(24시간):